1. Home
  2. NMR vs PODD Comparison

NMR vs PODD Comparison

Compare NMR & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMR
  • PODD
  • Stock Information
  • Founded
  • NMR 1925
  • PODD 2000
  • Country
  • NMR Japan
  • PODD United States
  • Employees
  • NMR N/A
  • PODD N/A
  • Industry
  • NMR Investment Bankers/Brokers/Service
  • PODD Medical/Dental Instruments
  • Sector
  • NMR Finance
  • PODD Health Care
  • Exchange
  • NMR Nasdaq
  • PODD Nasdaq
  • Market Cap
  • NMR N/A
  • PODD 19.0B
  • IPO Year
  • NMR 1961
  • PODD 2007
  • Fundamental
  • Price
  • NMR $6.11
  • PODD $259.37
  • Analyst Decision
  • NMR Hold
  • PODD Buy
  • Analyst Count
  • NMR 1
  • PODD 17
  • Target Price
  • NMR N/A
  • PODD $294.65
  • AVG Volume (30 Days)
  • NMR 553.2K
  • PODD 897.8K
  • Earning Date
  • NMR 04-25-2025
  • PODD 05-08-2025
  • Dividend Yield
  • NMR 3.29%
  • PODD N/A
  • EPS Growth
  • NMR 184.58
  • PODD 96.55
  • EPS
  • NMR 0.67
  • PODD 5.78
  • Revenue
  • NMR $11,988,627,534.00
  • PODD $2,071,600,000.00
  • Revenue This Year
  • NMR $47.37
  • PODD $20.58
  • Revenue Next Year
  • NMR N/A
  • PODD $17.41
  • P/E Ratio
  • NMR $9.15
  • PODD $44.73
  • Revenue Growth
  • NMR 30.73
  • PODD 22.07
  • 52 Week Low
  • NMR $4.66
  • PODD $160.19
  • 52 Week High
  • NMR $6.99
  • PODD $289.46
  • Technical
  • Relative Strength Index (RSI)
  • NMR 45.76
  • PODD 44.69
  • Support Level
  • NMR $6.53
  • PODD $258.25
  • Resistance Level
  • NMR $6.67
  • PODD $276.13
  • Average True Range (ATR)
  • NMR 0.10
  • PODD 8.60
  • MACD
  • NMR 0.00
  • PODD 0.94
  • Stochastic Oscillator
  • NMR 50.85
  • PODD 55.53

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it world-wide.

Share on Social Networks: